303 related articles for article (PubMed ID: 23883585)
1. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA
Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585
[TBL] [Abstract][Full Text] [Related]
2. Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.
Chakrabarti G; Silvers MA; Ilcheva M; Liu Y; Moore ZR; Luo X; Gao J; Anderson G; Liu L; Sarode V; Gerber DE; Burma S; DeBerardinis RJ; Gerson SL; Boothman DA
Sci Rep; 2015 Nov; 5():17066. PubMed ID: 26602448
[TBL] [Abstract][Full Text] [Related]
3. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
Huang X; Dong Y; Bey EA; Kilgore JA; Bair JS; Li LS; Patel M; Parkinson EI; Wang Y; Williams NS; Gao J; Hergenrother PJ; Boothman DA
Cancer Res; 2012 Jun; 72(12):3038-47. PubMed ID: 22532167
[TBL] [Abstract][Full Text] [Related]
4. Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
Huang X; Motea EA; Moore ZR; Yao J; Dong Y; Chakrabarti G; Kilgore JA; Silvers MA; Patidar PL; Cholka A; Fattah F; Cha Y; Anderson GG; Kusko R; Peyton M; Yan J; Xie XJ; Sarode V; Williams NS; Minna JD; Beg M; Gerber DE; Bey EA; Boothman DA
Cancer Cell; 2016 Dec; 30(6):940-952. PubMed ID: 27960087
[TBL] [Abstract][Full Text] [Related]
5. β-Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells.
Park EJ; Min KJ; Lee TJ; Yoo YH; Kim YS; Kwon TK
Cell Death Dis; 2014 May; 5(5):e1230. PubMed ID: 24832602
[TBL] [Abstract][Full Text] [Related]
6. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
Bey EA; Bentle MS; Reinicke KE; Dong Y; Yang CR; Girard L; Minna JD; Bornmann WG; Gao J; Boothman DA
Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11832-7. PubMed ID: 17609380
[TBL] [Abstract][Full Text] [Related]
7. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.
Silvers MA; Deja S; Singh N; Egnatchik RA; Sudderth J; Luo X; Beg MS; Burgess SC; DeBerardinis RJ; Boothman DA; Merritt ME
J Biol Chem; 2017 Nov; 292(44):18203-18216. PubMed ID: 28916726
[TBL] [Abstract][Full Text] [Related]
8. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.
Li LS; Bey EA; Dong Y; Meng J; Patra B; Yan J; Xie XJ; Brekken RA; Barnett CC; Bornmann WG; Gao J; Boothman DA
Clin Cancer Res; 2011 Jan; 17(2):275-85. PubMed ID: 21224367
[TBL] [Abstract][Full Text] [Related]
9. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.
Cao L; Li LS; Spruell C; Xiao L; Chakrabarti G; Bey EA; Reinicke KE; Srougi MC; Moore Z; Dong Y; Vo P; Kabbani W; Yang CR; Wang X; Fattah F; Morales JC; Motea EA; Bornmann WG; Yordy JS; Boothman DA
Antioxid Redox Signal; 2014 Jul; 21(2):237-50. PubMed ID: 24512128
[TBL] [Abstract][Full Text] [Related]
10. NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer.
Li LS; Reddy S; Lin ZH; Liu S; Park H; Chun SG; Bornmann WG; Thibodeaux J; Yan J; Chakrabarti G; Xie XJ; Sumer BD; Boothman DA; Yordy JS
Mol Cancer Ther; 2016 Jul; 15(7):1757-67. PubMed ID: 27196777
[TBL] [Abstract][Full Text] [Related]
11. NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.
Moore Z; Chakrabarti G; Luo X; Ali A; Hu Z; Fattah FJ; Vemireddy R; DeBerardinis RJ; Brekken RA; Boothman DA
Cell Death Dis; 2015 Jan; 6(1):e1599. PubMed ID: 25590809
[TBL] [Abstract][Full Text] [Related]
12. PCNA inhibition enhances the cytotoxicity of β-lapachone in NQO1-Positive cancer cells by augmentation of oxidative stress-induced DNA damage.
Su X; Wang J; Jiang L; Chen Y; Lu T; Mendonca MS; Huang X
Cancer Lett; 2021 Oct; 519():304-314. PubMed ID: 34329742
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation.
Dong Y; Bey EA; Li LS; Kabbani W; Yan J; Xie XJ; Hsieh JT; Gao J; Boothman DA
Cancer Res; 2010 Oct; 70(20):8088-96. PubMed ID: 20940411
[TBL] [Abstract][Full Text] [Related]
14. A self-amplified nanocatalytic system for achieving "1 + 1 + 1 > 3" chemodynamic therapy on triple negative breast cancer.
Zhou L; Chen J; Sun Y; Chai K; Zhu Z; Wang C; Chen M; Han W; Hu X; Li R; Yao T; Li H; Dong C; Shi S
J Nanobiotechnology; 2021 Sep; 19(1):261. PubMed ID: 34481495
[TBL] [Abstract][Full Text] [Related]
15. β-Lapachone increases phase II antioxidant enzyme expression via NQO1-AMPK/PI3K-Nrf2/ARE signaling in rat primary astrocytes.
Park JS; Lee YY; Kim J; Seo H; Kim HS
Free Radic Biol Med; 2016 Aug; 97():168-178. PubMed ID: 27242267
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Effect of β-Lapachone and Aminooxyacetic Acid on Central Metabolism in Breast Cancer.
Chang MC; Mahar R; McLeod MA; Giacalone AG; Huang X; Boothman DA; Merritt ME
Nutrients; 2022 Jul; 14(15):. PubMed ID: 35893874
[TBL] [Abstract][Full Text] [Related]
17. β-Lapachone Selectively Kills Hepatocellular Carcinoma Cells by Targeting NQO1 to Induce Extensive DNA Damage and PARP1 Hyperactivation.
Zhao W; Jiang L; Fang T; Fang F; Liu Y; Zhao Y; You Y; Zhou H; Su X; Wang J; Liu S; Chen Y; Wan J; Huang X
Front Oncol; 2021; 11():747282. PubMed ID: 34676172
[TBL] [Abstract][Full Text] [Related]
18. Synergistic enhancement of antitumor effect of β-Lapachone by photodynamic induction of quinone oxidoreductase (NQO1).
Lamberti MJ; Vittar NB; da Silva Fde C; Ferreira VF; Rivarola VA
Phytomedicine; 2013 Aug; 20(11):1007-12. PubMed ID: 23746950
[TBL] [Abstract][Full Text] [Related]
19. Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.
Beg MS; Huang X; Silvers MA; Gerber DE; Bolluyt J; Sarode V; Fattah F; Deberardinis RJ; Merritt ME; Xie XJ; Leff R; Laheru D; Boothman DA
J Surg Oncol; 2017 Jul; 116(1):83-88. PubMed ID: 28346693
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
